Emcure Pharmaceuticals Limited (IN:EMCURE)
:EMCURE
Want to see IN:EMCURE full AI Analyst Report?
EMCURE Stock Chart & Stats
₹1345.35
₹31.90(2.25%)
At close: 4:00 PM EST
₹1345.35
₹31.90(2.25%)
Day’s Range― - ―
52-Week Range₹1,046.80 - ₹1,830.35
Previous CloseN/A
Volume1.63K
Average Volume (3M)197.42K
Market Cap
₹328.46B
Enterprise Value₹342.49B
Total Cash (Recent Filing)₹6.02B
Total Debt (Recent Filing)₹16.59B
Price to Earnings (P/E)32.7
Beta0.82
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)22.89
Shares Outstanding189,589,550
10 Day Avg. Volume24,274
30 Day Avg. Volume197,417
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.11
Price to Sales (P/S)3.29
P/FCF Ratio61.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,970.00Price Target Upside46.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)61.74
Revenue Forecast (FY)₹103.48B
Bulls Say, Bears Say
Bulls Say
Revenue And Margin ImprovementSustained FY2026 revenue growth coupled with mid‑teens operating margins indicates improving underlying demand and better cost control. That combination supports durable earnings power, funds reinvestment in sales/production, and increases resilience to cyclical pressures over months.
Conservative Leverage & Improved ROELow debt relative to equity and rising ROE to the high‑teens provide financial flexibility and lower refinancing risk. This balance-sheet strength supports opportunistic capex or M&A, and reduces vulnerability to interest-rate moves or temporary cash shortfalls over a multi-month horizon.
Diversified Revenue Streams & Manufacturing ScaleA mix of domestic branded generics, international exports and contract manufacturing creates multiple stable revenue channels. Manufacturing scale and partner relationships help smooth demand swings, support margin retention, and underpin durable cash flows and customer stickiness over quarters.
Bears Say
Weak Cash ConversionFCF covering ~58% of net income and a year‑over‑year decline shows earnings are not fully converting to cash. This limits self‑funding for capex, reduces buffer for unexpected costs, and raises dependence on working‑capital management or external financing over the coming months.
Gross Margin VolatilityA sharp swing in reported gross margin suggests either one‑offs, input cost swings, or pricing pressure that undermines predictability. Persistent margin volatility complicates forecasting and strategic planning, raising execution risk for sustained profitability improvement over the medium term.
Rising Absolute DebtAlthough leverage ratios remain conservative, absolute debt has grown. Continued reliance on incremental borrowing to fund growth could elevate interest expense or refinancing needs, reducing financial flexibility and increasing downside risk if revenue or margins falter in coming quarters.
Emcure Pharmaceuticals Limited News
EMCURE FAQ
What was Emcure Pharmaceuticals Limited’s price range in the past 12 months?
Emcure Pharmaceuticals Limited lowest stock price was ₹1046.80 and its highest was ₹1830.35 in the past 12 months.
What is Emcure Pharmaceuticals Limited’s market cap?
Emcure Pharmaceuticals Limited’s market cap is ₹328.46B.
When is Emcure Pharmaceuticals Limited’s upcoming earnings report date?
Emcure Pharmaceuticals Limited’s upcoming earnings report date is Aug 18, 2026 which is in 89 days.
How were Emcure Pharmaceuticals Limited’s earnings last quarter?
Emcure Pharmaceuticals Limited released its earnings results on May 05, 2026. The company reported ₹14.1 earnings per share for the quarter, beating the consensus estimate of ₹13.6 by ₹0.5.
Is Emcure Pharmaceuticals Limited overvalued?
According to Wall Street analysts Emcure Pharmaceuticals Limited’s price is currently Undervalued.
Does Emcure Pharmaceuticals Limited pay dividends?
Emcure Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.21%. See more information on Emcure Pharmaceuticals Limited dividends here
What is Emcure Pharmaceuticals Limited’s EPS estimate?
Emcure Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emcure Pharmaceuticals Limited have?
Emcure Pharmaceuticals Limited has 189,589,550 shares outstanding.
What happened to Emcure Pharmaceuticals Limited’s price movement after its last earnings report?
Emcure Pharmaceuticals Limited reported an EPS of ₹14.1 in its last earnings report, beating expectations of ₹13.6. Following the earnings report the stock price went down -5.249%.
Which hedge fund is a major shareholder of Emcure Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:EMCURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
EMCURE Stock 12 Month Forecast
Average Price Target
₹1,970.00
▲(46.43% Upside)
Technical Analysis
AstraZeneca Pharma India Limited
―
Eris Lifesciences Ltd
―
JB Chemicals & Pharmaceuticals Ltd.
―
Dr. Lal PathLabs Limited
―
PFIZER LIMITED
―